Current filters:


1 to 9 of 14 results

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune


Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK pharma group slams NICE for failing to recognize nature of discovery and development


The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…


French price regulator authorizes reimbursement of InterMune's Esbriet


USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

French Transparency Commission issues favorable opinion on Esbriet


There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA


USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF


US biotech firm InterMune (Nasdaq: ITMN) has reported that new data at the European Respiratory Society…

BiotechnologyCardio-vascularEsbrietHealthcareInterMunePharmaceuticalResearchRespiratory and Pulmonary

1 to 9 of 14 results

Back to top